← All stocks

Kalaris Therapeutics, Inc.

KLRS Net buying
CIK 0001754068 #4344 in the set updated 17 Sep 2026
Bought (12 mo)
$6.18M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$12.87K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$12.87K
1 of 1 sales
Net
+$6.17M
+$6.17M against sales at will

By person

8 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
AKKARAJU SRINIVAS
Director
$6.18M (2)
+$6.18M
19,408
$93.74K
Hagen Brett R
Chief Accounting Officer
$12.87K (1)
−$12.87K
0
$0.00
−100.0%
Brainard Diana
Chief Executive Officer
723,363
$3.49M
−4.1%
Ferrara Napoleone
Director
504,000
$2.43M
Miller Edward
General Counsel
352,865
$1.70M
−1.4%
PATEL SAMIR CHANDRAKANT
Director
352,800
$1.70M
Sinha Vikas
See Remarks
49,129
$237.29K
−22.3%
Feinsod Matthew
Chief Medical Officer
4,030
$19.46K

No percentages here. This company's share count has moved by a factor of 22.9 over the window, from 5,043,357 to 115,536,550 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
AKKARAJU SRINIVAS
20 May 2026
Director
Buy indirect
244,300
$4.83
$1.18M
AKKARAJU SRINIVAS
18 Dec 2025
Director
Buy indirect
479,847
$10.42
$5.00M

What was left out

Form 4 filings counted 18
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 1,586,314
History held since 31 Jul 2020